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INTRODUCTION
The innate immune response represents the first line of defence against invading pathogens.
In addition to roles in direct recognition and engulfment of pathogens, macrophages promote antigen-specific adaptive immune responses. Pathogen antigens phagocytosed by macrophages undergo partial proteolysis by lysosomal peptidases before being loaded onto major histocompatibility complex (MHC) class II molecules for presentation to CD4 + T cells (1) , thereby generating both effector and memory immune responses. Thus, macrophages are critical in establishing communication between the innate and adaptive immune systems, and, in doing so largely determine the nature of the adaptive immune responses mounted which ensures that pathogens are either eliminated or their pathological effects are minimised.
Host defence peptides (HDPs; also referred to as antimicrobial peptides (AMPs) when they possess direct antimicrobial activity) represent an evolutionarily conserved component of innate immunity (2) . To date, over 1000 naturally-occurring HDPs/AMPs have been identified displaying great diversity in sequence lengths, structures and activities (3) . Since HDPs/AMPs share only limited sequence identity, they are broadly classified on the basis of homologous secondary structure as cathelicidins (linear α-helical peptides), defensins (βstrand peptides connected by disulfide bonds), and bactenecins (loop peptides) (4) . Despite such variation, HDPs/AMPs are generally cationic with hydrophobic faces (5, 6) , allowing many of them to interact with, and disrupt, negatively charged microbial cell membranes (7) .
Helminth parasites have devised many mechanisms for manipulating the responses of their hosts to allow their survival for long periods, and these often involve the secretion of specific molecules (8) . We recently reported the identification of a novel immunomodulatory molecule secreted by the animal and human pathogen Fasciola hepatica (termed helminth defence molecule; FhHDM-1) that exhibits structural, biochemical and functional characteristics similar to mammalian cathelicidin-like HDPs (9) . Phylogenetic analysis revealed that FhHDM-1 represented an archetypal member of a family of HDMs conserved throughout the Trematoda which includes major parasitic helminths of humans such Schistosoma mansoni, S. japonicum, Opisthorchis viverrini, Clonorchis sinensis and Paragonimus westermani. We isolated native and recombinant FhHDM-1 and showed that, like the mammalian cathelicidins, the precursor parent molecule is proteolytically processed (in this case by the parasite endopeptidase, cathepsin L1), to release a 34-residue C-terminal peptide (FhHDM p2) that forms an amphipathic helix. We proposed that the secretion of HDMs represented an exquisite example of parasite immunomodulation mediated by the secretion of a host-like molecular mimic that influences host innate immune responses.
Indeed, we demonstrated that both FhHDM-1, and FhHDM-1 p2 protected mice against LPSinduced inflammation by preventing the activation of macrophages (9) .
In the present study, we investigated the mechanism by which HDMs influence the function of macrophages. Our studies show that FhHDM-1 binds to macrophage plasma membrane lipid rafts, via selective interaction with phospholipids and/or cholesterol before being internalised by endocytosis. Following internalisation, FhHDM-1 is rapidly processed by lysosomal cathepsin L to release a 27 amino acid C-terminal peptide (containing the conserved amphipathic helix), which then prevents the acidification of the endolysosomal compartments by inhibiting vacuolar (v) ATPase activity. Preventing endolysosomal acidification impedes macrophage antigen processing by proteases, such as cathepsin L, preventing the presentation of peptides at the cell surface in conjunction with MHC class II to CD4+ T cells. Thus, we have elucidated a novel mechanism by which helminth pathogens alter innate immune cell function to prevent the development of effective adaptive immune responses, thereby ensuring prolonged parasite survival in the host.
MATERIALS AND METHODS

Recombinant FhHDM-1 and synthetic peptide analogues
Recombinant FhHDM-1 was expressed in E. coli and purified as previously described (9) .
Residual bacterial endotoxin was removed from all samples using RP-HPLC. Final endotoxin levels were measured using the Chromo-LAL assay kit (Associates of Cape Cod, East Falmouth, MA, USA) and shown to be 0.0029 EU/µg. A number of peptides were prepared based on the C-terminal alpha amphipathic helix of FhHDM-1 ( Fig. 1 ). FhHDM-1 peptide 1 (FhHDM-1 p1) corresponds to residues 51-80, and represents a truncation of the C-terminal amphipathic helix. FhHDM-1 p2 corresponds to residues 56-89 and matches the C-terminal fragment of FhHDM-1 containing the complete amphipathic helix that is released following cleavage by FhCL1 (9) . FhHDM-1 2Pro also corresponds to residues 56-89, but contains two proline substitutions (I69P and L80P) designed to disrupt the α-helix. Similarly, FhHDM-1 nonHP corresponds to residues 56-89 but contains six substitutions (I69R, I73Q, I75K, L76R, L84T and Y87K) designed to abolish the hydrophobic face of the amphipathic helix whilst preserving the α-helix. FhHDM-1 p3 matches the C-terminal fragment of FhHDM-1 containing the complete amphipathic helix that is released following cleavage by lysosomal cysteine peptidases as identified in the present study. The molar concentration of the HDM-derived peptides used is presented in
HDM peptides were labelled with Cy5 (GE Healthcare, Pittsburgh, PA) or Alexa Fluor 488 (Life Technologies, Vic, Australia) according to the manufacturer`s instructions.
All peptides were synthesised endotoxin-free by GL Biochem (Shanghai, China).
Primary human macrophages
Monocytes were isolated from buffy coats obtained from normal healthy adult donors and supplied by the Australian Red Cross Blood Service (Sydney, Australia). Mononuclear cells were purified from buffy coats by Ficoll-paque separation then CD14+ monocytes were enriched by positive selection (Miltenyi Biotec). Monocytes were differentiated into macrophages for up to 7 days in Iscove's Modified Dulbecco's Media (IMDM) supplemented with 2 % v/v human serum and their phenotype confirmed (expression of CD206) using an LSR II flow cytometer (BD Bioscience).
Confocal laser scanning microscopy
For confocal laser scanning microscopy (CLSM) experiments, human primary macrophages (1x10 6 ) derived from blood monocytes (Australian Red Cross, Sydney, Australia) were treated with 10 μg/mL of recombinant FhHDM-1 at 37ºC then washed and fixed with 4% paraformaldehyde and permeabilized with 0.1% Triton-X/PBS. After blocking, cells were incubated for 1 h at room temperature with primary antibody (1:2000) specific for His 6 tag (Life Technologies, Vic Australia). Cells were then washed and incubated with Alexa Fluor 488-conjugated (Life Technologies, Vic Australia) secondary antibody. To follow internalisation of FhHDM-1, macrophages (7x10 5 ) were simultaneously incubated with 10 μg/mL of Alexa Fluor 488-labelled FhHDM-1 and 60 nM LysoTracker (Life Technologies, Vic, Australia) for 45 min at 37ºC.
To examine the effect of FhHDM-1 on lysosome formation, macrophages (1x10 6 ) were incubated with either recombinant FhHDM-1 (10 μg/mL) or vehicle (PBS) for 20 h at 37ºC. After washing, cells were incubated with E. coli LPS (50 ng/mL; serotype 111:B4;
Sigma, NSW Australia) for 2 h and stained with LysoTracker, according to the manufacturer`s instructions. The cells were mounted in VectaShield ® (Vector Laboratories, Burlingame, CA, USA) and examined with a Nikon A1 confocal scanning laser microscope.
Images were rendered and analysed using NIS Elements software (Nikon, Melville, NY, USA).
3D-Structured Illumination Microscopy
Human primary macrophages (1x10 6 ) were treated with recombinant FhHDM-1 (10 μg/mL) for 2 h. Cells were incubated with 4 g/mL of cholera toxin subunit B Alexa Fluor 594conjugate (CT-B) for 20 min at 4°C, then fixed, and stained for FhHDM-1 using the His 6 antibody as described above. Imaging was performed using a DeltaVisionOMX 3D-Structured Illumination Microscope ® , version 3 (OMX 3D-SIM, Applied Precision Inc, Issaquah, USA). Solid state lasers (405, 488, 593 nm) were captured simultaneously using 3
Photometrics Cascade (Photometrics, Tucson, USA) back-illuminated EMCCD cameras (>90% QE) with a 512 x 512 CCD, and on-chip charge multiplication. All data capture used an Olympus UPlanSApo 100x 1.4NA oil objective and standard excitation and emission filter sets (in nm, 405 EX / 419-465 EM, 488 EX / 500-550 EM and 592.5 EX / 608-648 EM). 3D-SIM images were sectioned using a 125 nm Z-step size. Raw 3-phase images were reconstructed as previously described (10, 11) and the reconstructed images were rendered in 3D, with interpolation, using IMARIS v.7 software (Bitplane Scientific, Zurich, Switzerland).
Flow cytometry
RAW264.7 macrophages (1x10 6 /well) were cultured in 24-well plates with or without 0.25 g/mL trypsin (Life Technologies) for 1 h at 37°C. After washing, cells were incubated with Cy5-labelled recombinant FhHDM-1 (10 g/mL) for 30 min at 4°C. Binding of Cy5-FhHDM-1 and was assessed by flow cytometry. Cells were also stained for the surface markers CD11b and F4/80 using directly conjugated FITC-monoclonal antibodies (BD Bioscience, San Jose, CA, USA).
Sodium carbonate membrane extraction
RAW264.7 macrophages (2x10 7 ) were incubated with 20µg/mL of recombinant FhHDM-1 at 37°C for 2 h followed by cross-linking with 1% paraformaldehyde for 30 minutes. After sonication, membranes were prepared by centrifugation at 20,000g for 1 h. The membrane pellet was sequentially extracted with 0.1M Na 2 CO 3 (pH 11) and 1 % Triton X100 (TX100) to produce peripheral and integral membrane protein fractions respectively (12) . Samples were separated by non-reducing SDS-PAGE, transferred to nitrocellulose membranes and probed with anti-FhHDM-1 (9), anti-actin, and anti-calnexin antibodies (Sigma, NSW Australia). 
HDM-liposome interaction assay
Enrichment of lysosomal membranes
The method of Cohen et al. (15) was used to prepare a fraction enriched 10x for lysosomes.
Briefly, THP-1 or RAW264.7 macrophages (4x10 7 ) were sonicated on ice and a post-nuclear supernatant further centrifuged at 100,000g for 20 min to pellet lysosomes and endosomes.
The lysosome pellet was extracted with water for 5 min then centrifuged at 100,000g for 20 min. The supernatant was collected as the lysosome-soluble fraction (Ly-S) and the pellet as 
Purification of phagosomes using latex beads
The method of Shui et al. (16) was used to isolate phagosomes. Briefly, RAW264.7 macrophages were incubated with 0.8 M deep blue-dyed latex beads (Sigma, NSW, Australia) and allowed to internalize for 2 h at 37°C. The bead-containing phagosomes were purified using a sucrose gradient as described by Desjardins et al. (17) . Soluble and membrane protein fractions were prepared from the washed phagosomes as described above.
ATPase assay
ATPase activity was detected in macrophage Ly-M fractions using the ATPase Assay kit (Innova Biosciences, Babraham, Cambridge, UK) according to the manufacturer`s instructions. For inhibition assays, serial dilutions of HDMs were pre-incubated with Ly-M in 0.1 M Tris-HCl (pH 7.5) for 1 h at 37°C prior to incubation with the ATP substrate.
Processing of FhHDM-1 by macrophage lysosomal proteases
Lysosomal cathepsin activity in macrophage extracts was confirmed by incubating the soluble extract fraction (Ly-S) with the fluorogenic substrate Z-Leu-Arg-NHMec (Bachem, Bubendorf, Switzerland). Assays were performed (± 10 M E-64) at pH 5.5 as previously described (18) . To identify peptides resulting from proteolytic processing of FhHDM-1, samples of the 0 h, 2 h and 5 h Ly-S digests were analysed by Matrix Assisted Laser Desorption Ionisation (MALDI) mass spectrometry at the Australian Proteome Analysis Facility as previously described (9) . Spectra were acquired in positive mode in the mass range 2,000-20,000 Da with a mass accuracy of ± 50 Da.
Processing of
Antigen processing assays
Bone marrow-derived macrophages (BMDMs) were generated from the femurs of BALB/c mice and confirmed to be F4/80 + CD11b + by flow cytometry. FITC-conjugated casein (50 g/ml) was fed to RAW264.7 macrophages or BMDMs (3 x 10 6 ) with or without HDMs (5, 20 and 50 g/ml) or chloroquine (20 M). After 3 h incubation at 37°C, the cells were washed then lysed in RIPA buffer supplemented with protease inhibitor cocktail (Roche, NSW, Australia). Lysates were normalised for protein content and run on 4-12 % Bis-Tris gels (Life Technologies, Vic, Australia). Gels were scanned in the FITC channel using a PharosFX laser imaging system and normalized spot quantities were determined using PDQuest version 8.01 software (Bio-Rad, NSW, Australia).
Antigen presentation assays
BMDMs (1 x 10 5 ) were treated with HDMs (10-100 g/ml) for 2 h then pulsed overnight with 10 mg/ml full-length ovalbumin (OVA; Sigma, NSW, Australia) or pre-processed OVA 323-339 peptide (Anaspec, Fremont, CA, USA). The HDM-treated OVA-pulsed BMDMs were then co-cultured with 1 x 10 5 DO-11-10 T cell hybridomas (ECACC) for 24 h and levels of IL-2 in the culture medium measured by ELISA (BD Pharmingen, NSW, Australia).
RESULTS
FhHDM-1 binds to the macrophage plasma membrane via interaction with lipid rafts
To investigate how the cathelicidin-like molecule secreted by F. hepatica interacts with macrophages, we first incubated primary human macrophages with recombinant FhHDM-1 and examined its cellular localisation pattern using an anti-His 6 tag antibody. No fluorescence was observed in PBS-treated cells stained with the anti-His 6 tag antibody ( Fig indicating that FhHDM-1 interacts specifically with lipid rafts within the plasma membrane of primary human macrophages. FhHDM-1 also co-localised with CT-B on the surface of murine RAW264.7 macrophages (data not shown) demonstrating that its association with lipid rafts is not confined to human cells.
FhHDM-1 makes electrostatic interactions with the macrophage plasma membrane that are not associated with protein/receptor-binding
To investigate the biochemical nature of the FhHDM-lipid raft interaction, we performed an extraction of membranes, prepared from RAW264.7 macrophages treated with FhHDM-1.
When membrane proteins are associated through electrostatic forces (typical of both receptor-ligand interactions and peripheral membrane proteins), these complexes are easily disrupted and dissociated from the membrane. If, however, the protein is integral and associates with the membrane through hydrophobic interactions with the acyl core of the lipid bilayer, it will be highly resilient to dissociation. As expected, the peripheral membrane protein actin was only recovered in the Na 2 CO 3 aqueous fraction of the RAW264.7 macrophages (Fig. 3A) . By contrast, calnexin, which is an integral membrane protein, was found predominantly in the TX100 detergent fraction (Fig. 3A ). FhHDM-1 was only recovered in the Na 2 CO 3 aqueous fraction (Fig. 3A) suggesting that it interacts with plasma membrane/lipid raft components via electrostatic interactions. A similar result was obtained using membranes isolated from human THP-1 macrophages (Fig. S2C ).
Having established that FhHDM-1 binds the macrophage plasma membrane via electrostatic interactions, we next investigated whether this was indicative of protein/receptor-binding. To investigate this, RAW264.7 macrophages were incubated ± trypsin for 1 h at 37°C and the surface binding of Cy5-FhHDM-1 determined by flow cytometry. Immunostaining for the macrophage surface markers, CD11b and F4/80, was used to demonstrate the success of trypsinisation. As expected, CD11b and F4/80 fluorescence was markedly decreased in trypsinised macrophages compared with undigested cells (Fig. 3B) showing that trypsin effectively degraded surface expressed membrane proteins. In contrast, the ability of FhHDM-1 to bind to the macrophage surface was unaffected following trypsinization as the level of Cy5-fluorescence was almost identical in digested and undigested cells ( Fig. 3B ), suggesting that FhHDM-1 does not associate with surfaceexpressed macrophage proteins (at least those susceptible to trypsinization).
Having established that FhHDM-1 did not likely interact with proteins expressed on the macrophage surface we examined its potential to bind directly to phospholipid or other non-protein components of the plasma membrane. To assess whether FhHDM-1 interacts with membranes, LUVs composed of common phospholipids, were used as model membranes. As shown by silver-stained SDS-PAGE, FhHDM-1 bound directly to the LUVs, whereas the control protein BSA was found at the bottom of the gradient (Fig. 3C) .
A peptide corresponding to the conserved amphipathic helix of FhHDM-1 binds to liposomes
FhHDM-1 p2 is a 34 amino acid peptide containing the complete amphipathic helix of FhHDM-1 and is specifically released by proteolytic processing of the protein by the parasite protease FhCL1 (9) . Like the parent molecule, this peptide bound to LUVs. In contrast, FhHDM-1 nonHP, which is similar to FhHDM-1 p2 but has six amino acid substitutions that abolish the hydrophobic face of the amphipathic helix, did not associate with the LUV fraction but was instead detected in the bottom fraction of the sucrose gradient ( Fig. 3C ). This demonstrates the importance of the C-terminal amphipathic helix of FhHDM-1 for the association of this protein with cell-surface lipids.
We next investigated if the amphipathic helix preferentially bound particular phospholipid species. Monolayers of common phospholipids and cholesterol were prepared in ELISA plates and the binding of serially diluted biotinylated FhHDM-1 p2 was detected with a streptavidin-AP conjugate. The highest level of binding by FhHDM-1 p2 was to POPS, followed by DOPC and cholesterol (Fig. 3D ). In contrast, FhHDM-1 p2 showed weaker binding to POPE and little or no reactivity with POPC and sphingomyelin ( Fig. 3D ).
Sphingomyelin, POPC, and DOPC represent disaturated, monosaturated, and unsaturated phosphocholine lipids, respectively. FhHDM-1 p2 bound to DOPC (unsaturated) but also showed a high level of binding to POPS (monosaturated). This suggests that the selective phospholipid-binding properties of FhHDM-1 p2 are not simply due to lipid saturation status or to the presence of specific charged head groups in a particular lipid. Rather, binding ability appears to be related to the differential spacing of the head groups in the phospholipid bilayer, and also to the degree of oligomerisation of FhHDM-1 upon association with various phospholipid species (9, 20) . Whilst sphingomyelin and cholesterol are both key components of lipid rafts (21, 22) , FhHDM-1 p2 showed a much higher level of binding to cholesterol compared with sphingomyelin. Taken together, these data suggest that FhHDM-1 could bind to lipid rafts via interactions with cholesterol.
FhHDM-1 is internalised into endolysosomes and prevent their acidification via inhibition of vATPase activity
Using CSLM we found that Alexa Fluor 488-conjugated FhHDM-1 is internalised into the endolysosomal system of macrophages. FhHDM-1 co-localised with cytoplasmic vesicles that were visualised with LysoTracker (a lysosomotropic fluorescent dye that concentrates in acidic compartments) (see below and Fig. 7A ). FhHDM-1 also co-localised with Alexa Fluor 647-conjugated dextran (when co-incubated with RAW264.7 cells), which further confirms that FhHDM-1 enters the endolysosomal pathway ( Fig. 5A) .
To investigate its effect on lysosome function, primary human macrophages were incubated with recombinant FhHDM-1 or vehicle (PBS) prior to treatment with bacterial LPS to induce lysosome formation. Following this, the cells were stained with LysoTracker. In 51 % of the PBS-treated macrophages, numerous acidic (LysoTracker-positive) vesicles were distributed throughout the cytoplasm following incubation with LPS ( Fig. 4A, top panel) . In contrast, only 25 % of the macrophages pre-treated with FhHDM-1 showed any LysoTracker-positive staining in response to LPS with very few acidic compartments visible within the cytoplasm (Fig. 4A, bottom panel) . In addition, incubation of macrophages with
FhHDM-1, prior to the addition of E. coli bioparticles conjugated to a pH-sensitive fluorogenic dye (that increases in fluorescence with decreasing pH), resulted in a significant reduction of fluorescence (36%; p=0.01) in comparison to vehicle (PBS)-treated control cells ( Fig. 4A ). FhHDM-1 p2 exhibited a significantly greater effect on the fluorescence levels (66%; p=0.006), while FhHDM-1 nonHP had no effect on fluorescence levels compared to control cells. Strikingly, the vATPase inhibitor, folimycin showed a similar level of inhibition (59%; p=0.007) to FhHDM-1 p2 (Fig. 4B ). Treatment of the cells with NH 4 Cl, which raises lysosomal pH (23) FhHDM-p2, but not the parent FhHDM-1molecule, inhibits vATPase activity.
The above data shows that FhHDM-1 and FhHDM-p2 prevented the acidification of vesicles within the macrophage. We next investigated whether this was due to the inhibition of vATPase, which acts as the major regulating factor for the acidification of the endolysosomal lumen (24) . A lysosome-enriched fraction was prepared from THP-1 or RAW264.7 macrophages (both showed similar results as described below). The insoluble (membrane;
Ly-M) component of this fraction was positive for the lysosomal marker, LAMP-1, by immunoblot ( Fig. S3A ). Furthermore, soluble extracts (Ly-S) from this fraction were strongly positive for lysosomal cathepsin L activity using the diagnostic fluorescent substrate Z-Leu-Arg-NHMec (Fig. S3B) . The Ly-M fractions were treated with HDMs and assayed for ATPase activity. As shown in Figure 6 , FhHDM-1 p2 inhibited ATPase activity associated with lysosomal membranes (equivalent to vATPase activity) in a concentration-dependent manner (IC50 = 0.9 μM). Strikingly, full-length recombinant FhHDM-1, as well as synthetic peptide analogues with a truncated C-terminal amphipathic helix (FhHDM-1 p1), disrupted helical structure (FhHDM-1 2Pro) or where the hydrophobic face of the C-terminal amphipathic helix has been abolished (FhHDM-1 nonHP), did not inhibit ATPase activity even at the highest concentrations tested (Fig. 6 ). Similar results were obtained using membranes isolated from phagosomes purified using latex beads (data not shown).
FhHDM-1 is internalised by macrophages and processed by lysosomal cathepsin L to release vATPase inhibitory peptides
Observations that FhHDM-1-derived peptides inhibit vATPase, while the full-length parent molecule does not, may have been attributable to the processing of FhHDM-1 by endogenous proteases to release the C-terminal amphipathic helix following internalisation into the endolysosome. Our data showing that the cysteine peptidase inhibitor, E-64, could inhibit the effect of FhHDM-1 on endolysosome acidification indicated an involvement of this class of peptidase (see above). Therefore, full-length FhHDM-1 was incubated with the Ly-S fraction (i.e. native contents of macrophage lysosomes) at pH 5.5 and the reaction products were analysed by Western blot, using an anti-FhHDM-1 antibody. The blots showed that the 9.2 kDa band corresponding to full-length recombinant FhHDM-1 had slightly decreased in intensity concurrent with the appearance of a number of smaller protein fragments over time ( Fig. 7B) . These fragments were not detected when the reaction was performed in the presence of E-64 demonstrating that the full-length protein had been cleaved by a lysosomal cysteine peptidase. When the digests were performed using purified human cathepsin L (hCatL) endopeptidase (a key cysteine peptidase involved in antigen processing within the lysosome) a similar pattern of FhHDM-1 peptide fragments was observed (Fig. 7B ).
The FhHDM-1 Ly-S digests (0, 2 and 5 h reactions) were analysed by MALDI TOF MS ( Table 1; (Table 1) suggesting that the C-terminal peptide is processed further by lysosomal aminopeptidases or dipeptidyl/tripeptidyl aminopeptidase creating the final cleavage site at Asp 63 observed following digestion with the native lysosomal extract (Ly-S).
Based on the putative hCatL cleavage site, a 27-residue synthetic peptide (FhHDM-1 p3) corresponding to the C-terminal region of the native molecule was designed for subsequent analysis. This peptide is eight residues shorter at the N-terminus and one residue longer at the C-terminal compared to FhHDM p2 (see Fig. 1 ). Strikingly, FhHDM-1 p3
inhibited vATPase activity in a concentration-dependent manner as effectively as FhHDM-1 p2 (Fig. 7C) .
We also designed a number of synthetic peptides with various N-and C-terminal truncations of the amphipathic helix in order to determine the minimal sequence required for vATPase inhibition (Fig. 1 ). However, none of these truncated peptides inhibited vATPase activity ( Fig. 7C ). Of particular note is peptide FhHDM-1 48-70, which is shorter than
FhHDM-1 p3 at the N-terminal end by only three amino acids (Asn 64 -Leu 65 -Gly 66 ) and
indicates that this motif may be important for vATPase inhibition.
FhHDM-1 inhibits endolysosomal antigen processing and MHC class II antigen presentation
By preventing the acidification of endolysosomes, via inhibition of vATPase activity, we hypothesised that FhHDM-1 would inhibit antigen processing by macrophages as the activity of lysosomal proteases and hence the degradation of foreign proteins, is optimal at low pH (25) . We therefore exposed murine macrophages to the MHC class II antigen casein (conjugated to FITC to enable fluorescent in-gel detection), and analysed its degradation by SDS-PAGE. Whilst FITC-casein was rapidly degraded in PBS-treated cells, antigen degradation was blocked when cells were co-incubated with chloroquine (Clq) a weak base known to elevate endolysosomal pH (23) . Similarly, FhHDM-1 blocked processing of FITCcasein in a concentration-dependent manner (Fig. 8A-B) . Whilst FhHDM-1 p3 had no measurable effect on FITC-casein degradation, FhHDM-1 p2 had a small inhibitory effect at higher concentrations that was not seen with peptide nonHP (Fig. 8A-B) . It is interesting that FhHDM-1 showed a greater inhibitory effect on FITC-casein processing than FhHDM-1 p2
( Figure 8A) whilst FhHDM-1 p2 had a greater effect than FhHDM-1 on endolysosomal alkalization ( Figure 4B ). Whilst unexpected, these observations are reproducible and may be due to differences in the cell type used and assay sensitivity.
We next determined if FhHDM-1 could effect antigen presentation by macrophages.
To do this we used OVA-specific T cell hybridoma DO-11-10 cells whose proliferative response to OVA 323-339 peptide, presented with MHC class II, can be quantified by measuring the levels of secreted interleukin-2 (IL-2) (26, 27) . DO-11-10 T cells activated in vitro by OVA-pulsed murine bone marrow derived macrophages, that were pre-treated with FhHDM-1, produced significantly less IL-2 (p = 0.001) than those exposed to PBS-treated macrophages (Fig. 8C ). This effect was not observed when the pre-processed OVA [323] [324] [325] [326] [327] [328] [329] [330] [331] [332] [333] [334] [335] [336] [337] [338] [339] peptide was used as antigen or when OVA-pulsed macrophages were pre-treated with peptide nonHP (data not shown). Therefore, FhHDM-1 modulated the ability of macrophages to present antigen.
DISCUSSION
In response to stimulation by microbes and pro-inflammatory mediators, mammalian innate immune cells release an array of host defence peptides (HDPs) that work cooperatively to perform broad-spectrum antimicrobial activities (28) (29) (30) . In addition to their direct antimicrobial activity, recent studies have shown that some HDPs (in particular the human cathelicidin-derived peptide LL-37) also regulate aspects of innate immunity that can protect against excessive inflammation stimulated by the LPS endotoxin (reviewed in (31) ). They achieve this by interrupting key stages of LPS-mediated cell signalling, thereby preventing activation of macrophages and dendritic cells via toll-like receptors (TLR) (32) (33) (34) . These mechanisms include direct binding and sequestration of LPS, preventing its interaction with TLRs and blocking the LPS-LPS-binding protein (LBP) interaction, both important early stage events in the recognition of microbial infections (35) (36) (37) . We previously demonstrated that the helminth pathogen F. hepatica secreted a small molecule, FhHDM-1, which exerted similar effects on LPS signalling, including direct binding of LPS, thereby reducing its interaction with both LBP and to the macrophage surface (9) . FhHDM-1 exhibited a striking ability to protect mice against LPS-induced inflammation by preventing the release of inflammatory mediators from macrophages (9) . We proposed that HDMs are secreted by the helminth parasites to protect the host against excessive LPS-induced inflammation that would occur following disruption of the intestinal epithelial barrier (and concomitant systemic transfer of luminal bacteria), during parasite invasion and migration (9) . Thus, by preventing the activation of innate immune responses normally induced by LPS, the helminth enhances the survival of the host and, accordingly, its own longevity. However, since we discovered that HDMs are also rapidly internalised into macrophages we surmised that they have an additional, novel, mechanism of action that influences macrophage function.
Confocal microscopy revealed that the initial interaction of FhHDM-1 with macrophages occurs through association with lipid rafts on the cell surface. Despite extensive trypsinization of cell surface proteins, the interaction between FhHDM-1 and the macrophage was not affected, indicating that FhHDM-1 binds to non-proteinaceous lipid raft components.
One putative binding partner for FhHDM-1 is cholesterol, a key sterol component of lipid rafts (22) , since this molecule contains a cholesterol-binding motif, (L/V-[X] 1-5 -Y-[X] 1-5 -R/K, spanning residues V 45 TKAYEKAR 53 ) that is highly conserved across all known cholesterolbinding proteins (38) . However, FhHDM-1 p2, which lacks the cholesterol binding motif due to an N-terminal truncation, nevertheless binds cholesterol in a concentration-dependent manner. While the motif may enhance the specificity of the FhHDM-1-cholesterol interaction, or perhaps dictate the orientation of HDM-binding at the cell surface, it alone is clearly not essential for cholesterol-binding.
It is also probable that FhHDM-1 binds to lipid rafts via the HDM C-terminal amphipathic helix since a similar structural element of the tyrosine kinase interacting protein (Tip) of Herpesvirus saimiri has been shown to target Tip to lipid rafts and directs its lysosomal trafficking (39) . The human cathelicidin-derived peptide, LL-37, also interacts with lipid rafts on the cell surface prior to endocytosis by CHO-K1 cells (40) . However, LL-37 cannot bind to cholesterol (indeed its presence strongly reduces the ability of LL-37 to interact with phospholipid membranes; 41,42) and, therefore, more likely interacts with the P2X 7 receptor, which is found within lipid rafts (43) . While LL-37 directly induces the release of cytokines from monocytes (notably IL-1β), via direct activation of P2X 7 receptors (44), we have found that FhHDM-1 p2 does not activate this receptor (data not shown). This highlights key functional differences between the two molecules and how they interact with macrophages.
Following initial binding to lipid rafts, FhHDM-1 was internalised into LysoTrackerpositive vesicles and co-localised with fluorescently-labelled dextran, which is known to enter cells via the endolysososmal system (45) . Pre-incubation of macrophages with FhHDM- Alvarado, unpublished data).
Acidification of endolysosomal compartments is primarily mediated by vATPase, a transmembrane complex comprised of cytosolic (V 1 ) and membrane bound (V 0 ) subunits (46) . We found that FhHDM-1 p2 inhibited ATPase activity associated with macrophage endolysosomal membranes in a concentration-dependent manner. Since in assembled, functional vATPase complexes, ATP hydrolysis by the cytoplasmic V 1 domain drives proton transport through the membrane bound V 0 domain from the cytoplasm to the endolysosomal lumen (46) prevention of this process provides a novel, and direct, biochemical mechanism by which the secreted parasite molecule impairs acidification of endolysosomal vesicles.
Consistent with the data derived from our E. coli bioparticle assays, vATPase inhibition required an intact HDM amphipathic helix (peptide nonHP was non-inhibitory), which further highlights the importance of the C-terminal tail of FhHDM-1. It is interesting to note that the human salivary HDP histatin-5, which possesses anti-Leishmania activity also targets a proton pump, the mitochondrial F 1 F 0 -ATPase (ATP synthase), of the parasite (47).
However, this peptide does not adopt an amphipathic structure (48) and does not display primary sequence identity with FhHDM-1 p2, although both peptides possess short α-helices.
While the full-length parent FhHDM-1 molecule was capable of uncoupling endolysosomal acidification in macrophages, it was unable to directly inhibit vATPase activity. For this, FhHDM-1 needs to be proteolytically processed within the macrophage. However, given that the low pH microenvironment within the endolysosomal lumen ensures the activity of around 40 types of acid hydrolases, including peptidases, lipases, phosphatases, nucleases and glycosidases (46) , and that pH regulates the release of internalised ligands from their endosomal receptors (52) , is it probable that FhHDM-1induced uncoupling of endolysosomsal acidification will have a broad span of effects on macrophage function.
The targeting of vATPase by HDMs represents a novel mechanism of immunomodulation by a secreted parasite molecule. The inhibition of antigen processing and presentation by macrophages by uncoupling endolysosomal acidification has not previously been described as a mechanism by which a helminth parasite evades the protective responses of the host (see Fig. 9 for an overview of this process). In the context of parasite infection, our data suggest that the secretion of FhHDM-1 by juvenile worms would suppress the development of parasite-specific immune responses generated in response to subsequent developmental stages. The broader, detrimental, consequences of this would be to prevent the development of antigen-specific responses to unrelated third-party antigens, such as a coinfecting microbial pathogen or delivery of a vaccine, as is often the case for human populations in areas of endemic helminth infection. On the other hand, a deeper understanding of the mechanism of action of HDMs could be of great benefit, potentially providing a therapeutic where the inhibition of vATPase or lysosomal acidification halts the progress of pathology, such as in cancer or osteoarthritis (53, 54) . The effect of HDMs on ATPase activity associated with lysosomal membranes prepared from RAW264.7 macrophages was assessed using the ATPase Assay kit (Innova Biosciences).
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